ImmunityBio Responds to FDA Marketing Concerns with Formal Clarification

ImmunityBio formally responds to FDA allegations, clarifying promotional claims while reporting $100M funding and clinical progress for its bladder cancer drug ANKTIVA.

Biotechnology firm ImmunityBio has formally addressed allegations from the U.S. Food and Drug Administration (FDA) concerning potentially misleading promotional claims. The company's recently submitted response provides a straightforward rebuttal to the regulatory body's criticisms, which had previously impacted its share price.

A Two-Pronged Defense

The FDA's warning letter, issued in mid-March, centered on statements made by company founder Dr. Patrick Soon-Shiong during a podcast interview and an alleged television commercial. ImmunityBio's official reply offers a clear defense on both counts.

Regarding the podcast comments, the company clarified that Dr. Soon-Shiong's remarks were forward-looking statements about the future potential of drug development, not claims about current product capabilities. More notably, the firm contested the second allegation entirely. ImmunityBio stated that the television advertisement cited by the FDA was never actually broadcast.

This formal clarification aims to resolve regulatory uncertainties that emerged after reports of the FDA's warning letter circulated. The company's flagship product is the FDA-approved immunotherapy ANKTIVA, which is used in combination with BCG to treat specific forms of bladder cancer.

Operational Momentum Amid Regulatory Dialogue

Separate from the regulatory discussions, ImmunityBio continues to advance its business operations. In late March, the company's management secured $100 million in fresh capital. Of this total, $75 million originated from non-dilutive funding sources. These resources are earmarked for global expansion and further development of the firm's immunotherapy pipeline.

Concurrently, the biotech company is reporting clinical progress for ANKTIVA. A pivotal study for the treatment of non-muscle invasive bladder cancer recently achieved its necessary statistical endpoint. The product has also received positive international regulatory signals, including a conditional marketing authorization recommendation from the European Medicines Agency and approvals in Saudi Arabia.

Based on the current clinical data, ImmunityBio plans to submit a supplemental Biologics License Application (sBLA) for ANKTIVA in the United States later this year. The combination of secured financing and the now-official response to the FDA creates a defined operational foundation for the company's near-term objectives.